It was our aim in this study to conduct a human trial testing the glucose sensor accuracy and infusion site patency over four days of the trocar-free CGM-IS in adults with T1D who are managed with insulin pumps and CGM. The gene discussed is INS; the disease is type 1 diabetes mellitus.